GDC-0425
- Generic Name
- GDC-0425
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N5O
- CAS Number
- 1627539-18-7
- Unique Ingredient Identifier
- 4N173XZ7SX
- Background
GDC-0425 is under investigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma).
- Associated Conditions
- -
- Associated Therapies
- -
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01359696
- Locations
- 🇺🇸
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
🇺🇸Karmanos Cancer Institute.., Detroit, Michigan, United States
🇫🇷Institut Gustave Roussy; Ser. de Med. Nucleaire; Cancerologie Endo, Villejuif, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath